Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
The UK Government’s announcement to be an AI superpower will impact every L&D professional’s future.
The UK government announced it’s AI Opportunities Action Plan, which has three key goals:
To lay the foundations for AI
To change lives by embracing AI
To secure the…
Tom Jackson highlights a recent report demonstrating how organisations can incorporate AI within their learning and development practices.
Organisations are using AI solutions to quickly craft tailored learning experiences for each team member and/or team need, making the learning process…
Attendees
Sponsors and
Exhibitors
AI Training
for Doctors Workshops
Contact us